N/A N=16 Surface Stimulation for Female Sexual Dysfunction
Female Sexual Dysfunction
Primary: 6 Weeks - Total FSFI Score — 26.0; 17.4 score on a scale — p=0.109
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=61 A Mindfulness-based Intervention for Older Women With Low Sexual Desire
Hypoactive Sexual Desire Disorder · Sexual Dysfunction · Female Sexual Dysfunction
Primary: Feasibility - Number of Enrolled Women Participating in All Sessions — 15; 22 Participants — p=0.027
N/A N=220 Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients
End Stage Renal Disease · Sexual Dysfunction, Physiological · Pain
Primary: Change in Pain, Sexual Dysfunction, and Depression Symptoms — -3.12; -3.7; 0.62; 0.71 units on a scale
N/A N=148 Randomized Comparison of Mindfulness Versus Group Support for Treatment of Low Sexual Desire in Women
Low Female Sexual Desire
Primary: Female Sexual Distress Scale-Revised (FSDS-R) — 22.88; 25.68; 23.02; 23.87 units on a scale
Phase 4 N=40 Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder
Primary: Changes in Blood Oxygen Level Dependent (BOLD) Signal Change on Functional MRI — 9.98; 7.67 BOLD signal change
Phase 3 N=217 Effects of SH T00658ID on Libido
Contraception · Libido
Primary: Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS) — 6.45; 5.98 scores on a scale
N/A N=12 Erectile Rating During the Treatment of Rectal Cancers Localized
Rectal Cancer Stage I
Primary: Proportion of Patients With Erectile Dysfunction Induced by Medical and Surgical Treatment of Rectal Cancer — 0 Participants
Phase 2 N=80 Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men
Sexual Dysfunctions, Psychological · Hypoactive Sexual Desire Disorder · Erectile Dysfunctions
Primary: Number of Participants With a Score of ≤2 (Much/Very Much Improved) on the Clinical Global Impression Scale Adapted for Sexual Function (CGI-SF) at Week 6 Between…
Phase 4 N=83 Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning
Healthy
Primary: Change in 17-OH Pregnenolone — 120; 158; 171; 170 ng/dl — p=>0.8
Phase 2 N=7 Double-Blind Naltrexone in Compulsive Sexual Behavior
Compulsive Sexual Behavior
Primary: Yale Brown Obsessive Compulsive Scale Modified for Compulsive Sexual Behavior (YBOCS) — 8; 9.33 units on a scale
Phase 3 N=117 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Alopecia
Primary: Number of Participants With Adverse Events (AE) Related to Sexual Function in the Double-blind Treatment Period — 5; 9 Participants — p=0.27
N/A N=45 The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
Multiple Sclerosis
Primary: Sexual Dysfunction (as Measured by the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-19) ) — -0.697 units on a scale
N/A N=79 Trial of Tibial Nerve Stimulation for Treating Sexual Dysfunction
Female Sexual Dysfunction
Primary: Female Sexual Function Index (FSFI) — 16.72; 16.88; 22.02; 21.22 score on a scale
N/A N=25 Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function
Hypertension · Female Sexual Dysfunction
Primary: Change in Female Sexual Function Index — 1.24; 1.42 units on a scale
Phase 3 N=378 A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.
Erectile Dysfunction
Primary: Change From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship…
Phase 4 N=361 Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers
Healthy Volunteers
Primary: Change From Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Full Analysis…
Phase 3 N=447 Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
Treatment Outcome
Primary: Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8 — 8.8; 6.6 scores on a scale — p=0.013
N/A N=553 Characteristics of Sexual Dysfunction in Patients With Lung Cancer
Lung Cancer · Sexual Dysfunction
Primary: Number of Participants With Different Type, Frequency and Severity of Sexual Dysfunction — 71; 275; 76; 51 Participants
N/A N=127 The Human Papilloma Virus Effect on Sexual Life
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
Phase 4 N=176 Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied
Impotence
Primary: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index at the End of the DB Treatment (Week 8) — 80.27; 62.15 scores on a scale — p=<0.0001
Phase 4 N=489 Prospective Sexual Function Study for BPH Subjects
Prostatic Hyperplasia
Primary: Changes From Baseline (BL) in Total Score From the Full Men's Sexual Health Questionnaire (MSHQ) at 12 Months — -0.7; -8.7 Scores on a scale — p=<0.001
Phase 3 N=16 Safety and Effectiveness Study of Maca Root to Treat Antidepressant-Induced Sexual Dysfunction
Depression · Sexual Dysfunction
Primary: Change in Massachusetts General Hospital Sexual Dysfunction Inventory Scores — .249; .017 score on a scale — p=.016
N/A N=20 Penile Nerve Stimulation for Treatment of Delayed Ejaculation
Delayed Ejaculation
Primary: International Index of Erectile Function (IIEF) Scale Score — 7.5; 9.7 score on a scale
Phase 2 N=397 Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Female Sexual Arousal Disorder · Hypoactive Sexual Desire Disorder
Primary: The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE) — 0.2; 0.6; 0.7; 0.8 SSEs — p=<0.05
Phase 3 N=945 Flibanserin Versus Placebo in Premenopausal Women With HSDD
Sexual Dysfunctions, Psychological
Primary: Change From Baseline in the Frequency of Satisfying Sexual Events as Measured by the eDiary. — 1.2; 1.5; 0.9 events per month
Phase 2 N=239 IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)
Premature Ejaculation
Primary: Change From Baseline in Geometric Mean (GM) Intravaginal Ejaculatory Latency Time (IELT) Over the Treatment Assessment Period — 42.6; 39.7; 44.5; 29.2 Seconds
Phase 4 N=40 Depression, Epinephrine, and Platelet Function
Major Depressive Disorder
Primary: Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8 — 5; 9; 2; 4 participants — p=.918
N/A N=56 Dyspareunia and Central Sensitization
Endometriosis · Central Sensitisation · Dyspareunia
Primary: Deep Dyspareunia Score — 3.08 scores on a scale
N/A N=606 Stress, Sex, and the Generalization of Fear
Psychological Stress
Primary: Fear-potentiated Startle Responses to the CS+ and CS- During Acquisition — 52.059; 19.162; 44.388; 9.732 Fear-potentiated startle (microvolts) — p=0.453
N/A N=47 Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction
Female Sexual Dysfunction · Polycystic Ovary Syndrome
Primary: Sexual Function — 24.8; 26.0 score on a scale — p=0.71